Archive · 23 Aug 2026
Apollo, Max Bet on India’s Hospital Capacity Growth
Apollo Hospitals and Max Healthcare run hospitals in India.
The article says India does not have enough hospital beds for its population.
Apollo plans to add thousands of beds, and Max plans to reach 10,000 beds by FY30.
Both companies are also focusing on complex treatments such as cancer, heart, and brain care.
More older people and higher incomes could increase demand for healthcare.
Patients from other countries are also contributing to hospital revenue.
Apollo’s latest reported profit grew faster than its revenue, while Max’s profit grew more slowly.
The article says both companies may grow, but their shares are already valued more highly than the industry average.
Apollo plans 3,475 additional beds by FY30, while Max targets 10,000 beds from about 6,100.
The article cites India’s shortage of 100,000 beds and significantly lower bed density than the UK, United States, and Japan.
High-acuity treatments account for 62% of Apollo’s inpatient revenue and are being expanded by both hospital operators.
Apollo’s latest-quarter income rose 20.57% and profit after tax increased 38.32%; Max’s income grew 16.57% and PAT rose 4.8%.
Both stocks trade above industry valuation medians, with Apollo at a P/E of 60 and Max near 65, according to the article.
- Who
- Apollo Hospitals Enterprise Limited and Max Healthcare Institute Limited.
- What
- The article examines their hospital expansion plans, healthcare growth prospects, financial results, and stock valuations.
- When
- The latest quarter discussed is Q1 FY27; valuation data is stated to be from 14 August 2026, with expansion targets through FY30.
- Where
- India, including Apollo’s broader expansion plans and Max Healthcare’s concentration in Tier-1 cities.
- Why
- The article attributes potential growth to India’s hospital-bed shortage, aging population, higher disposable income, premium healthcare demand, and medical tourism.
Growth Case
Valuation And Execution Caution
Hospital expansion
Growth Case
The article argues that India’s reported 100,000-bed shortage and low bed density create a long-term opportunity for Apollo and Max to add capacity.
Valuation And Execution Caution
Expansion requires substantial execution and investment, and the article does not establish that planned beds will produce returns matching current expectations.
Premium healthcare demand
Growth Case
Aging, higher disposable income, high-acuity treatment, and medical tourism could support higher revenue per patient and premium services.
Valuation And Execution Caution
Both stocks already trade above industry valuation medians, so future growth may be partly reflected in their prices.
Company performance
Growth Case
Apollo’s latest-quarter PAT increased 38.32%, while both companies reported year-over-year income growth and positive long-term share-price gains.
Valuation And Execution Caution
Max’s PAT grew only 4.8% as total expenses rose 18.5%, and its share price declined 17.5% over the previous year, according to the article.
- India bed shortage
- Apollo Managing Director Sunita Reddy is cited as saying India is short of 100,000 hospital beds.
- Bed density
- The article cites 0.5 beds per 1,000 people in India, compared with 2.5 in the UK, 2.9 in the United States, and 13 in Japan.
- Apollo expansion
- Apollo plans to add 3,475 beds by FY30; its active bed capacity was close to 9,620 at the end of FY26.
- Max expansion
- Max Healthcare plans to increase capacity to 10,000 beds by FY30 from about 6,100.
- International revenue
- International patients account for 9% of Max Healthcare’s hospital revenue and 8% of Apollo’s total revenue; Max reported international patient revenue of Rs 247 crore, up 18% year over year.
- Latest-quarter performance
- Apollo reported income of Rs 7,092 crore and PAT of Rs 610 crore; Max reported income of Rs 2,406 crore and PAT of Rs 323 crore.
- Relative valuation
- Apollo’s P/E was 60 and Max Healthcare’s was 65.14, versus an industry median of 45.28, according to the cited data.